KarXT, a proprietary oral modulator of muscarinic receptors, is the Company's lead product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist
, to preferentially stimulate muscarinic receptors in the central nervous system (CNS).
YUPELRI inhalation solution, a long-acting muscarinic antagonist
is the first and only once-daily, nebulized bronchodilator approved for the maintenance treatment of chronic obstructive pulmonary disease in the U.S., the companies said in a statement.
That approach came as news to many meeting attendees, based on results of an audience poll in which 76% of attendees picked triple therapy for a 65-year-old male with COPD and frequent exacerbations who was taking only a long-acting muscarinic antagonist
That approach came as news to many internists, at least going by results of an audience poll in which 76% of attendees picked triple therapy for a 65-year-old male with COPD and frequent exacerbations despite having used a long-acting muscarinic antagonist
The products are a muscarinic antagonist
indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Solifenacin succinate tablets are a muscarinic antagonist
indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
Long-Acting Muscarinic Antagonist
in Combination with Long-Acting Beta[sub]2-Adrenoceptor Agonist
Fifty-two weeks of a once-daily combination of fluticasone furoate (an inhaled glucocorticoid), umeclidinium (a long-acting muscarinic antagonist
), and vilanterol (a long-acting ?2-agonist) was compared with fluticasone furoate-vilanterol and umeclidinium-vilanterol.
With all, our objective was to evaluate the role of the acetylcholine-COX pathway by blockade with muscarinic antagonist
(Atropine) and blockade with an unspecific inhibitor of cyclooxygenases (Indomethacin) in the arterial vessel of dorsal, mesenteric, pulmonary and iliac arteries in C.
Trimbow is the first 3-in-1 combination inhaler containing an inhaled corticosteroid (ICS) / long-acting [beta]2-agonist (LABA) / long-acting muscarinic antagonist
(LAMA) containing beclometasone dipropionate (BDP; 87mcg), formoterol fumarate (FF, 5mcg) and glycopyrronium (GB, 9mcg), administered as a twice-daily fixed-dose in a pressurised metered-dose inhaler (pMDI) extrafine formulation.
The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist
(LAMA) and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK's Ellipta dry powder inhaler.